Gain Therapeutics is a biotechnology company developing small molecule therapeutics to treat diseases across, several therapeutics areas, including, central nervous system disorders, lysosomal storage disorders, metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. Co.'s primary product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease, including restoration of GCase function, reduction of toxic lipid substrates and toxic forms of alpha-synuclein, improved survival of dopaminergic neurons, and increase of dopamine levels and improved locomotor function in animal models. We show 13 historical shares outstanding datapoints in our GANX shares outstanding history coverage, used to compute GANX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing GANX market cap history over the course of time is important for investors
interested in comparing GANX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of GANX versus a peer is one thing; comparing
GANX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like GANX can fluctuate over the course of history.
With this page we aim to empower investors researching GANX by allowing them to research the GANX market cap history. |
Free GANX Email Alerts:
Video: The Importance of Market Cap
